Alnylam Pharmaceuticals | ALNY - Loan Capital


Alnylam Pharmaceuticals reported $2.48B in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.48B 931K Mar/2026
Amgen USD 51.89B 1.88B Mar/2026
Arrowhead Research USD 1.23B 687.3M Mar/2026
BioCryst Pharmaceuticals USD 395.2M 33.48M Mar/2026
BioMarin Pharmaceutical USD 1.43B 833.11M Mar/2026
Incyte USD 29.41M 785K Mar/2026
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
Moderna USD 603M 7M Mar/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 29.59B 5.35B Dec/2025
PTC Therapeutics USD 286.94M 1.74B Mar/2026
Regeneron Pharmaceuticals USD 1.99B 719.7M Mar/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 15.72B 150.06M Dec/2025
Sarepta Therapeutics USD 838.16M 9.19M Mar/2026
Takeda JPY 4.37T 99.51B Mar/2026
Tectonic Therapeutic USD 43K 57K Dec/2025
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025
Xencor USD 82.12M 5.64M Mar/2026